Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas

Phase 1 Suspended 36 enrolled City of Hope Medical Center National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the safety of giving multiple intracerebral doses of NSC-CRAd-S-pk7 to treat patients with glioblastoma at first recurrence. NSC-CRAd-S-pk7 consists of neural stem cells that can target glioblastoma cells and carry a virus, which can kill cancer cells. Giving multiple doses of NSC-CRAd-S-pk7 may kill more tumor cells.

Timeline

Start: 2023-05-02
Primary completion: 2026-08-07
Completion: 2026-08-07

Outcome

Outcome not reported

Stopped: “Safety issues”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NSC-CRAd-S-pk7	Cell therapy	—	Other

Indications

No indication recorded.